Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference31 articles.
1. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.
2. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European organization for research and treatment of cancer-gynaecological cancer group; NCIC clinical trials group. neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.
3. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33.
4. Yoshikawa K, Fukuda T, Uemura R, Matsubara H, Wada T, Kawanishi M, et al. Age-related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer. Mol Clin Oncol. 2018;9(3):329–34.
5. Deng F, Xu X, Lv M, Ren B, Wang Y, Guo W, et al. Age is associated with prognosis in serous ovarian carcinoma. J Ovarian Res. 2017. https://doi.org/10.1186/s13048-017-0331-6.